Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone

Clinical Prostate Cancer

Volumn 1, Issue 3, 2002, Pages 145-152

  Saad, Fred ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

Bisphosphonate; Bone metastases; Prostatic carcinoma; Skeletal complications

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANEMIA; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEVER; FLU LIKE SYNDROME; HUMAN; INCIDENCE; MALE; MORTALITY; MYALGIA; NAUSEA; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL; PREDICTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0042510488     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2002.n.016     Document Type: Review

References (46)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1999: National Cancer Institute. Available at: http://seer.cancer.gov/cst/1973_1999/. Accessed December 18, 2002.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49:33-64.
3. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88(suppl 12):S2989-S2994.
4. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80(suppl 8):S1588-S1594.
5. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164:1248-1253.
6. Smith JA, Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 1999; 54(suppl 6A):S8-S14.
7. Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82:858-864.
8. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952-1956.
9. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166:1724-1728.
10. Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001; 58(suppl 1):S101-S107.
11. Kiratli BJ, Srinivas S, Perkash I, et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57:127-132.
12. Poor G, Atkinson EJ, O'Fallon WM, et al. Determinants of reduced survival following hip fractures in men. Clin Orthop 1995; 319:260-265.
13. Poor G, Atkinson EJ, Lewallen DG, et al. Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporos Int 1995; 5:419-426.
14. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002; 168:1005-1007.
15. Oefelein MG, Ricchiuti VS, Conrad PW, et al. Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era. Urology 2002; 60:120-124.
16. Janjan N. Bone metastases: approaches to management. Semin Oncol 2001; 28(suppl 11):S28-S34.
17. Pelger RC, Soerdjbalie-Maikoe V, Hamdy NA. Strategies for management of prostate cancer-related bone pain. Drugs Aging 2001; 18:899-911.
18. Soerdjbalie-Maikoe V, Pelger RM, Lycklama a Nijeholt GB, et al. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med 2002; 29:494-498.
19. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11:59-65.
20. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
21. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090.
22. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16:593-602.
23. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20:3719-3736.
24. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387.
25. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002; 55:210-224.
26. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000; 60:6001-6007.
27. Smith JA, Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141:85-87.
28. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol 1992; 24:159-166.
29. Kylmala T, Taube T, Tammela TL, et al. Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br J Cancer 1997; 76:939-942.
30. Ernst DS, Tannock IF, Venner PM, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc Am Soc Clin Oncol 2002; 21:177a (Abstract #705).
31. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-1468.
32. Strang P, Nilsson S, Brandstedt S, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 1997; 17:4717-4721.
33. Lipton A, Small E, Saad F, et al. The new bisphosphonate, ZOMETA® (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: a comparison to pamidronate. Cancer Invest 2001; 20(suppl 2):S45-S47.
34. Hasling C, Charles P, Mosekilde L. Etidronate disodium in the management of malignancy-related hypercalcemia. Am J Med 1987; 82:51-54.
35. Carey PO, Lippert MC. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology 1988; 32:403-407.
36. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 2001; 165:136-140.
37. Theriault RL. Fitting new modalities into practice guidelines. Oncology (Huntingt) 1997; 11:145-149.
38. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
39. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 2001; 92:1444-1450.
40. Saad F, Gleason D, Small E, et al. Zoledronic acid is effective for the treatment of bone metastases in men with advanced prostate cancer. Poster presented at: 3rd International Consultation on Prostate Cancer; June 21-23, 2002; Paris, France.
41. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9:745-751.
42. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558-567.
43. Smith MR, Shasha D, Mansour R, Zinner N. ZOMETA® increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Presented at 3rd North American Symposium: Skeletal Complications of Malignancy; Bethesda, Maryland.
44. Fourneau I, Broos P. Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chir Belg 1998; 98:255-260.
45. Katzer A, Meenen NM, Grabbe F, et al. Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002; 122:251-258.
46. Healey JH, Brown HK. Complications of bone metastases: surgical management. Cancer 2000; 88(suppl 12):S2940-S2951.